[A25-86] Omaveloxolone (Friedreich’s ataxia) – Benefit assessment according to §35a Social Code Book V
Last updated 01.10.2025
Project no.:
A25-86
Commission:
Commission awarded on 01.07.2025 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Indication:
Patients ≥ 16 years with Friedreich’s ataxia
Result of dossier assessment:
Added benefit not proven
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
DOI:
https://doi.org/10.60584/A25-86
| Project no. | Title | Status |
|---|---|---|
| G24-06 | Omaveloxolone (Friedreich’s ataxia) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V | Commission completed |